326 related articles for article (PubMed ID: 28075040)
1. N-acetyl-seryl-aspartyl-lysyl-proline mediates the anti-fibrotic properties of captopril in unilateral ureteric obstructed BALB/C mice.
Chan GCW; Wu HJ; Chan KW; Yiu WH; Zou A; Huang XR; Lan HY; Lai KN; Tang SCW
Nephrology (Carlton); 2018 Apr; 23(4):297-307. PubMed ID: 28075040
[TBL] [Abstract][Full Text] [Related]
2. N-Acetyl-seryl-aspartyl-lysyl-proline Alleviates Renal Fibrosis Induced by Unilateral Ureteric Obstruction in BALB/C Mice.
Chan GC; Yiu WH; Wu HJ; Wong DW; Lin M; Huang XR; Lan HY; Tang SC
Mediators Inflamm; 2015; 2015():283123. PubMed ID: 26508815
[TBL] [Abstract][Full Text] [Related]
3. Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.
Peng H; Carretero OA; Liao TD; Peterson EL; Rhaleb NE
Hypertension; 2007 Mar; 49(3):695-703. PubMed ID: 17283252
[TBL] [Abstract][Full Text] [Related]
4. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.
Cavasin MA; Rhaleb NE; Yang XP; Carretero OA
Hypertension; 2004 May; 43(5):1140-5. PubMed ID: 15037553
[TBL] [Abstract][Full Text] [Related]
5. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal inflammation and tubulointerstitial fibrosis in rats.
Wang M; Liu R; Jia X; Mu S; Xie R
Int J Mol Med; 2010 Dec; 26(6):795-801. PubMed ID: 21042772
[TBL] [Abstract][Full Text] [Related]
6. The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.
Kumar N; Nakagawa P; Janic B; Romero CA; Worou ME; Monu SR; Peterson EL; Shaw J; Valeriote F; Ongeri EM; Niyitegeka JM; Rhaleb NE; Carretero OA
Am J Physiol Renal Physiol; 2016 May; 310(10):F1026-34. PubMed ID: 26962108
[TBL] [Abstract][Full Text] [Related]
7. Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.
Rhaleb NE; Peng H; Harding P; Tayeh M; LaPointe MC; Carretero OA
Hypertension; 2001 Mar; 37(3):827-32. PubMed ID: 11244003
[TBL] [Abstract][Full Text] [Related]
8. Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.
Romero CA; Kumar N; Nakagawa P; Worou ME; Liao TD; Peterson EL; Carretero OA
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F195-F203. PubMed ID: 30403163
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.
Rasoul S; Carretero OA; Peng H; Cavasin MA; Zhuo J; Sanchez-Mendoza A; Brigstock DR; Rhaleb NE
J Hypertens; 2004 Mar; 22(3):593-603. PubMed ID: 15076166
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy.
Tang SC; Leung JC; Chan LY; Eddy AA; Lai KN
Kidney Int; 2008 Feb; 73(3):288-99. PubMed ID: 18033243
[TBL] [Abstract][Full Text] [Related]
11. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.
Zuo Y; Chun B; Potthoff SA; Kazi N; Brolin TJ; Orhan D; Yang HC; Ma LJ; Kon V; Myöhänen T; Rhaleb NE; Carretero OA; Fogo AB
Kidney Int; 2013 Dec; 84(6):1166-75. PubMed ID: 23739235
[TBL] [Abstract][Full Text] [Related]
12. The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases.
Kumar N; Yin C
Pharmacol Res; 2018 Aug; 134():268-279. PubMed ID: 29990624
[TBL] [Abstract][Full Text] [Related]
13. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells.
Kanasaki K; Koya D; Sugimoto T; Isono M; Kashiwagi A; Haneda M
J Am Soc Nephrol; 2003 Apr; 14(4):863-72. PubMed ID: 12660320
[TBL] [Abstract][Full Text] [Related]
14. Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction.
Le Y; Zheng Z; Xue J; Cheng M; Guan M; Xue Y
J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27913661
[TBL] [Abstract][Full Text] [Related]
15. N-acetyl-seryl-aspartyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis.
Omata M; Taniguchi H; Koya D; Kanasaki K; Sho R; Kato Y; Kojima R; Haneda M; Inomata N
J Am Soc Nephrol; 2006 Mar; 17(3):674-85. PubMed ID: 16452498
[TBL] [Abstract][Full Text] [Related]
16. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney and brain.
Hrenak J; Paulis L; Simko F
Curr Pharm Des; 2015; 21(35):5135-43. PubMed ID: 26350537
[TBL] [Abstract][Full Text] [Related]
17. New anti-fibrotic mechanisms of n-acetyl-seryl-aspartyl-lysyl-proline in silicon dioxide-induced silicosis.
Sun Y; Yang F; Yan J; Li Q; Wei Z; Feng H; Wang R; Zhang L; Zhang X
Life Sci; 2010 Aug; 87(7-8):232-9. PubMed ID: 20624403
[TBL] [Abstract][Full Text] [Related]
18. High plasma level of N-acetyl-seryl-aspartyl-lysyl-proline: a new marker of chronic angiotensin-converting enzyme inhibition.
Azizi M; Ezan E; Nicolet L; Grognet JM; Ménard J
Hypertension; 1997 Nov; 30(5):1015-9. PubMed ID: 9369248
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis.
Mnguni AT; Engel ME; Borkum MS; Mayosi BM
PLoS One; 2015; 10(12):e0143338. PubMed ID: 26656271
[TBL] [Abstract][Full Text] [Related]
20. Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Castoldi G; di Gioia CR; Bombardi C; Perego C; Perego L; Mancini M; Leopizzi M; Corradi B; Perlini S; Zerbini G; Stella A
Clin Sci (Lond); 2009 Oct; 118(3):211-20. PubMed ID: 20310083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
